Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
QuintilesIMS
Daiichi Sankyo
Merck
US Department of Justice
Teva

Generated: August 19, 2019

DrugPatentWatch Database Preview

Patent: 8,562,986

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,562,986
Title:Engineered anti-alpha V-integrin hybrid antibodies
Abstract: The invention relates to engineered antibodies which specifically bind to integrin receptors, especially the alpha V integrin receptor subunit. The antibodies comprise the antigen binding sites (CDRs) of a known mouse anti-integrin antibody, as well as hybrid light chain variable sequences, mutated heavy chain variable sequences (Frs) and modified heavy chain constant sequences. The novel antibodies have improved immunogenic and expression properties and elicit excellent anti-angiogenic as well as anti-tumor activities in humans in monotherapy but also and above all in combination with other angiogenesis and tumor inhibiting agents.
Inventor(s): Goodman; Simon (Griesheim, DE), Hahn; Diane (Seeheim-Jugenheim, DE), Mitjans; Francesc (Igualada, ES), Adan; Jaume (Mataro, ES), Lo; Kin-Ming (Lexington, MA)
Assignee: Merck Patent GmbH (Darmstadt, DE)
Application Number:12/669,408
Patent Claims:see list of patent claims

Details for Patent 8,562,986

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Try a Free Trial Merck Patent GmbH (Darmstadt, DE) 2027-07-17 RX Orphan search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Federal Trade Commission
QuintilesIMS
Chubb
Queensland Health
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.